Adicet Bio says prula-cel Phase 1 lupus study shows 54% DORIS remission at 12 months
Bitget2026/09/28 10:45- Adicet Bio reported updated Phase 1 data for prula-cel in systemic lupus erythematosus, including patients with lupus nephritis.
- Results were released now, with an investor webcast scheduled for today.
- Patients showed sustained disease control with many reaching remission, alongside broad discontinuation of immunosuppressants and meaningful steroid tapering.
- Safety looked manageable, supporting outpatient use, with no severe cytokine release syndrome or serious neurologic immune-related events reported.
- Start-up activities for a single-arm pivotal lupus nephritis study are planned for 4Q/2026, with possible expansion into non-renal lupus.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
